Compare DexCom, Inc. (DXCM) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Oscar Health Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Oscar Health Inc trades at $29.48 (market cap $8.63B). The key difference: DexCom, Inc. is far larger — about 3.9× Oscar Health Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Oscar Health Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | OSCR | |
|---|---|---|
Market Cap | $33.79B | $8.63B |
Sector | Health | Health |
52-Week High | $89.53 | $32.18 |
52-Week Low | $54.84 | $10.85 |
Enterprise Value | $33.24B | $4.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Oscar Health (OSCR) trades at $29.61, up 7.01% today, with technical indicators showing a bearish trend but oversold RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.1 per share, and raised its full-year outlook amid membership growth and cost control. Revenue surged 70% year-over-year to $4.9 billion for the first half of 2026, driving a net income turnaround to $551 million for the full year 2026.
The outlook is positive with robust revenue growth and profitability improvements, though risks include competitive pressures and reliance on Obamacare policies. Analysts have a consensus price target of $32.50, suggesting moderate upside, but hold ratings dominate due to execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
